{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:37:47Z","timestamp":1759451867196,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","issue":"32","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novartis Vaccines Division"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.vaccine.2019.06.076","type":"journal-article","created":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T17:46:46Z","timestamp":1562176006000},"page":"4460-4467","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antibody persistence and booster response following MenACWY-CRM vaccination in children as assessed by two different assay methods"],"prefix":"10.1016","volume":"37","author":[{"given":"Nicola P.","family":"Klein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stan L.","family":"Block","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon","family":"Essink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3996-7361","authenticated-orcid":false,"given":"Silvia","family":"Barbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Smolenov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavitra","family":"Keshavan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.06.076_b0005","unstructured":"World Health Organization. Meningococcal meningitis. Available from: http:\/\/www.who.int\/mediacentre\/factsheets\/fs141\/en\/ [accessed 2019 January 19]."},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2019.06.076_b0010","doi-asserted-by":"crossref","first-page":"B26","DOI":"10.1016\/j.vaccine.2011.12.032","article-title":"The changing and dynamic epidemiology of meningococcal disease","volume":"30","author":"Halperin","year":"2012","journal-title":"Vaccine"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2019.06.076_b0015","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2011.12.062","article-title":"Meningococcal disease: clinical presentation and sequelae","volume":"30","author":"Pace","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.06.076_b0020","first-page":"116","article-title":"Clinical presentation of meningococcal disease in childhood","volume":"53","author":"Sabatini","year":"2012","journal-title":"J Prev Med Hyg"},{"key":"10.1016\/j.vaccine.2019.06.076_b0025","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1478-7954-11-17","article-title":"Global epidemiology of invasive meningococcal disease","volume":"11","author":"Jafri","year":"2013","journal-title":"Popul Health Metr"},{"key":"10.1016\/j.vaccine.2019.06.076_b0030","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.jadohealth.2016.03.041","article-title":"Deciphering the burden of meningococcal disease: conventional and under-recognized elements","volume":"59","author":"Martinon-Torres","year":"2016","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.vaccine.2019.06.076_b0035","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jadohealth.2016.04.012","article-title":"The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines","volume":"59","author":"Pelton","year":"2016","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.vaccine.2019.06.076_b0040","unstructured":"World Health Organization. Invasive meningococcal disease-Serogroup distribution; 2018. Available from: https:\/\/www.who.int\/emergencies\/diseases\/meningitis\/serogroup-distribution-2018.pdf?ua=1 [accessed 2019 May 14]."},{"key":"10.1016\/j.vaccine.2019.06.076_b0045","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1080\/21645515.2018.1532248","article-title":"Recent changes in the epidemiology of Neisseria meningitidis serogroup W across the world, current vaccination policy choices and possible future strategies","volume":"15","author":"Booy","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.06.076_b0050","unstructured":"European Medicines Agency. Menveo: EPAR \u2013 Product information. Available from http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001095\/WC500090147.pdf [accessed 2019 May 14]."},{"key":"10.1016\/j.vaccine.2019.06.076_b0055","unstructured":"U.S. Food and Drug Administration. Package insert \u2013 Menveo: highlights of prescribing information. Available from: http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM201349.pdf [accessed 2019 May 14]."},{"key":"10.1016\/j.vaccine.2019.06.076_b0060","doi-asserted-by":"crossref","first-page":"7865","DOI":"10.1016\/j.vaccine.2010.09.092","article-title":"Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2\u201310 years of age","volume":"28","author":"Halperin","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.06.076_b0065","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1080\/14760584.2018.1521280","article-title":"An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine","volume":"17","author":"Keshavan","year":"2018","journal-title":"Expert Rev Vaccin"},{"key":"10.1016\/j.vaccine.2019.06.076_b0070","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1128\/CVI.00207-09","article-title":"Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra","volume":"16","author":"Reisinger","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2019.06.076_b0075","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijid.2014.03.1390","article-title":"Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlers","volume":"26","author":"Tregnaghi","year":"2014","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.06.076_b0080","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1080\/21645515.2015.1136040","article-title":"Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants","volume":"12","author":"Baxter","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.06.076_b0085","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/INF.0b013e31823dce5c","article-title":"Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants","volume":"31","author":"Klein","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2019.06.076_b0090","first-page":"780","article-title":"Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England","volume":"10","author":"Andrews","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2019.06.076_b0095","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2019.06.076_b0100","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1084\/jem.129.6.1327","article-title":"Artenstein MS. Human immunity to the meningococcus. II. Development of natural immunity","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2019.06.076_b0105","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1016\/j.vaccine.2015.07.019","article-title":"Serum bactericidal antibody assays \u2013 the role of complement in infection and immunity","volume":"33","author":"McIntosh","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.06.076_b0110","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1086\/599117","article-title":"Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents","volume":"49","author":"Jackson","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.06.076_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2014.02.025","article-title":"Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents","volume":"164","author":"Baxter","year":"2014","journal-title":"J Pediatr"},{"key":"10.1016\/j.vaccine.2019.06.076_b0120","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1097\/INF.0000000000000438","article-title":"Antibody persistence after primary and booster doses of a quadrivalent meningococcal conjugate vaccine in adolescents","volume":"33","author":"Baxter","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2019.06.076_b0125","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1016\/j.vaccine.2015.02.049","article-title":"Antibody persistence 5 years after vaccination at 2 to 10 years of age with quadrivalent MenACWY-CRM conjugate vaccine, and responses to a booster vaccination","volume":"33","author":"Block","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.06.076_b0130","doi-asserted-by":"crossref","first-page":"881","DOI":"10.4161\/hv.6.11.12849","article-title":"Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo\u00ae) or Menactra\u00ae among healthy adolescents","volume":"6","author":"Gill","year":"2010","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2019.06.076_b0135","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1097\/INF.0b013e318279ac38","article-title":"Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents","volume":"32","author":"Jacobson","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2019.06.076_b0140","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1016\/j.vaccine.2012.02.046","article-title":"Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations","volume":"30","author":"Khatami","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.06.076_b0145","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1471-2334-13-116","article-title":"Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study","volume":"13","author":"Borja-Tabora","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2019.06.076_b0150","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.4161\/hv.22166","article-title":"Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers","volume":"8","author":"Vesikari","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.06.076_b0155","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1128\/IAI.01191-08","article-title":"Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera","volume":"77","author":"Granoff","year":"2009","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2019.06.076_b0160","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1586\/14760584.2015.1016915","article-title":"Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigen","volume":"14","author":"Seib","year":"2015","journal-title":"Expert Rev Vaccin"},{"key":"10.1016\/j.vaccine.2019.06.076_b0165","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.vaccine.2011.10.068","article-title":"Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source","volume":"30","author":"Gill","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.06.076_b0170","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1128\/IAI.69.3.1568-1573.2001","article-title":"Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection","volume":"69","author":"Borrow","year":"2001","journal-title":"Infect Immun"},{"issue":"Suppl 5","key":"10.1016\/j.vaccine.2019.06.076_b0175","doi-asserted-by":"crossref","first-page":"S554","DOI":"10.1093\/cid\/civ504","article-title":"Human complement bactericidal responses to a group A meningococcal conjugate vaccine in Africans and comparison to responses measured by 2 other group A immunoassays","volume":"61","author":"Price","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.06.076_b0180","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1093\/infdis\/jiv211","article-title":"The diversity of meningococcal carriage across the African Meningitis Belt and the impact of vaccination with a group A meningococcal conjugate vaccine","volume":"212","author":"MenAfriCar Consortium","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.06.076_b0185","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1186\/s12879-014-0663-4","article-title":"Persistent low carriage of serogroup A Neisseria meningitidis two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac","volume":"14","author":"Kristiansen","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2019.06.076_b0190","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/cid\/cis892","article-title":"Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity","volume":"56","author":"Kristiansen","year":"2013","journal-title":"Clin Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19308539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19308539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:33:34Z","timestamp":1759401214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19308539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":38,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0264410X19308539"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.06.076","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody persistence and booster response following MenACWY-CRM vaccination in children as assessed by two different assay methods","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.06.076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}